Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. - Wikidata - wikimedia - TriplyDB

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

http://www.wikidata.org/entity/Q35677168

about

Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations.Long-acting slow effective release antiretroviral therapy.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs Development and characterization of a long-acting nanoformulated abacavir prodrug Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.Creation of a long-acting nanoformulated dolutegravir.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.

P2860

Q21133553-1EB49C38-7596-4ED5-B7BD-91C26862CFFA Q28394163-47E4AA9C-960B-4E63-848B-80C1402703FA Q28551873-A9AA92FC-2F7B-4626-A213-BD9944DDB8B0 Q30603781-548ED2BE-D39F-4A71-A043-0CE9427DE698 Q33625213-59476594-CBAA-4F39-B7D3-77C34FA4725E Q34512904-9C77079E-B659-475B-8B6C-EDC56BA52453 Q34745586-30D91AA6-CC88-4044-9CF6-A7DA9DB3FEFF Q35153311-7EB973FE-4804-4917-AB45-B8B521FEC976 Q35979166-1F6495BC-4B38-416A-A610-92EA6CD20F16 Q36020685-FFDEAD62-0FD4-46C7-ACFD-808D3D38CBD1 Q36262152-5D67A091-508F-49B6-84DC-971979420248 Q36603756-6AE4EF8A-FC31-4248-8E48-8A4E2DF54E29 Q36875347-1BF39C45-AAB5-47F2-85D8-A48ECF441A81 Q36969787-F58E3025-E1BC-4887-863B-481EB4BE8A98 Q37188867-5DE96B53-C130-4E90-A150-BA68898A5D46 Q37704651-B563D596-D6F0-4BD9-806B-14C8519CC4BA Q38992323-36A5254D-E780-4CDC-98AA-5661AFC4D514 Q41280373-BEF2677F-B114-4A58-812D-1B7FC247A5F9 Q41905223-E0B87A59-FF3C-4E90-AADD-EB0D8A0617AD Q47603651-2E9695B8-30CF-452A-AA6F-6C559EF14BEE Q50051618-1011C9DA-EA4E-4D5D-9D5E-5755E3BBF9B1 Q54267469-A7332E24-029D-403D-81C8-1BC47C8A8295

P2860

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

http://www.wikidata.org/entity/Q35677168

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

@ast

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

@en

type

label

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

@ast

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

@en

prefLabel

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

@ast

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

@en

P1433

Q35677168-199DA888-60C8-43C7-8A28-D492A2C376B7

P1476

Q35677168-642FC75F-5A8E-4EB8-AAC0-73CC5292EEB3

P2093

Q35677168-21369956-BAF4-4217-8FF1-68CFEF182EFC

Q35677168-46F057D2-73E2-4850-A11D-44F8CDAF09A9

Q35677168-5FD2B661-9A96-48D3-BC7E-82F0BE03AE93

Q35677168-6E004C34-B4A3-4915-AF05-D6FBE68D6335

Q35677168-6FD3B059-8E9F-46BF-A537-019E45FB06FD

Q35677168-9C56590F-7BD8-4CCD-BFB0-BA55D2DC25BA

Q35677168-A6EBA132-CF1F-456B-A311-8E18AFAFA5E9

Q35677168-BA3C931A-5C8D-4C9C-BE3F-72445D43DC83

Q35677168-C8B909C5-A333-4AC7-96D3-96F948B41512

Q35677168-CB9175F9-4CE7-45FC-8EA6-C14554B680D6

P2860

Q35677168-013B8916-FCC8-45C2-B880-58B56649AD7E

Q35677168-08349AE6-C9FE-419A-860A-AAA766011B64

Q35677168-0BE5FC90-0E05-49A1-822D-83569B078318

Q35677168-0E0CCD64-A85D-4F94-BBDB-2CE3AA8E07E4

Q35677168-16CCBCA3-773E-4E29-A6DE-656C52AC2034

Q35677168-1F50B5E4-288C-4EAB-A1DF-DDD1A820C55A

Q35677168-20D5F508-8678-466D-A90F-515BE1AB7E91

Q35677168-2EF27499-4432-44AC-AD63-ADA6849052A7

Q35677168-3657314E-B038-45E4-9609-18068829B052

Q35677168-40CB0FB0-D6F3-438D-B538-1A66CD22E050

P304

Q35677168-EC6717E1-644B-4444-AE77-7AC1D6169BAA

P31

Q35677168-F0300009-1EEC-4CA9-8E3B-91C1D3A2850E

P356

Q35677168-2FCC0025-8C40-4376-8000-1D2DEC454277

P407

Q35677168-56A2D67D-C3CA-4DD2-B667-B35E092FB0CD

P478

Q35677168-9D51BB5D-0DE3-4F00-B3E3-06CDAD6CC3D2

P50

Q35677168-42F841E1-5119-4D61-AB56-4B524C71CA2C

P577

Q35677168-912C0319-9900-4ABB-A732-15276EE651C7

P698

Q35677168-9B3E0176-F74F-46A7-86EB-549B73842886

P921

Q35677168-5E76CE5F-FC6A-4B75-BA1D-E1F2827FEC57

P932

Q35677168-736A0693-583C-4EA2-A336-11AB0CEE7183

P356

P1433

International Journal of Nanomedicine

P1476

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

@en

P2093

Alexander V Kabanov

http://www.w3.org/2001/XMLSchema#string

Andrea Martinez-Skinner

http://www.w3.org/2001/XMLSchema#string

Ari S Nowacek

http://www.w3.org/2001/XMLSchema#string

Georgette Kanmogne

http://www.w3.org/2001/XMLSchema#string

Han Chen

http://www.w3.org/2001/XMLSchema#string

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

JoEllyn McMillan

http://www.w3.org/2001/XMLSchema#string

R Lee Mosley

http://www.w3.org/2001/XMLSchema#string

Ram S Veerubhotla

http://www.w3.org/2001/XMLSchema#string

Shantanu Balkundi

http://www.w3.org/2001/XMLSchema#string

P2860

Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus.

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Nanosizing of poorly water soluble compounds using rotation/revolution mixer.

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice

Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation.

Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

The critical need for alternative antiretroviral formulations, and obstacles to their development.

P304

3393-3404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJN.S27830

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22267924

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3260033

http://www.w3.org/2001/XMLSchema#string